| MORPHOSYS AG O.N. | 113.60 / +5.19% |
| Date/Time | 08/03 / 14:00 |
| Chg. / Chg.(%) | 5.60 / +5.19% |
| Bid | 113.55 / 55 |
| Ask | 113.70 / 267 |
| Open | 118.00 |
| Previous Close | 108.00 |
| High | 122.85 |
| Low | 112.70 |
| Volume [EUR] | 24,872,153.20 |
| Volume [Units] | 214,811 |
| Price fixings | 2900 |
| ISIN | DE0006632003 |
| Security | MOR |
| Exchange | Xetra |
| Type | Stock |
| Exchange | Last | Volume | |
|---|---|---|---|
| Xetra | 113.60 |  |
214,811 |
| Cboe Europe .. | 113.50 | |
38,613 |
| TradeGate | 114.000 | |
37,785 |
| Turquoise | 113.53 | |
19,119 |
| London Inter.. | 113.65 | |
15,833 |
| Cboe Europe .. | 113.70 | |
7,728 |
| Stuttgart | 113.600 | |
4,356 |
| Frankfurt | 115.0000 | |
3,584 |
| gettex | 113.750 | |
928 |
| München | 115.65 | |
373 |
| Berlin | 115.30 | |
120 |
| Düsseldorf | 124.10 | |
70 |
| Hannover | 122.00 | |
0 |
| Hamburg | 122.00 | |
0 |
| Lang & Schwa.. | 113.600 |  |
|
| Vienna Globa.. | 108.10 | 0 | |
| SIX Swiss Ex.. | 102.00 | ||
| Nasdaq Other.. | 140.6500 | 650 | |
| EUREX | Options | ||
News
- I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China
04/27/2020 / 22:01 - GlobeNewswire - MOR106 clinical development in atopic dermatitis stopped for futility
10/28/2019 / 21:45 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:02 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:01 - GlobeNewswire - Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over
01/31/2019 / 13:36 - GlobeNewswire
Real-time